Sugammadex, SNaPP, and Postoperative Pulmonary Complications
When a large, pragmatic trial compares the two drugs we reach for most often at the end of a case, I pay attention—even when the absolute difference looks modest on the page. The SNaPP trial, published in The Lancet Respiratory Medicine and summarized for clinicians by Pulmonology Advisor, asked whether reversing aminosteroid neuromuscular blockade with sugammadex, rather than neostigmine, lowers postoperative pulmonary complications or death after major abdominal or thoracic surgery.
In brief: among nearly 3,500 adults aged 40 and older, the composite of pulmonary complications or death occurred in about 19% with sugammadex versus about 21.5% with neostigmine (risk ratio roughly 0.88). The signal was driven mainly by less atelectasis. Pneumonia, aspiration, mortality, unplanned ICU or high-dependency admission, days alive and at home, and later quality of life did not meaningfully differ. That pattern matches what many of us already feel in the OR: sugammadex often gives a cleaner, more predictable reversal and a smoother path to extubation, but it is not a magic shield against every postoperative lung event.
How I read this as a clinician
SNaPP strengthens the case for treating sugammadex as a reasonable first-line choice when we are reversing rocuronium or vecuronium in higher-risk abdominal and thoracic cases—especially when residual weakness or delayed wake-up would be costly. It does not, in my view, mean every healthy outpatient now “requires” sugammadex, nor that neostigmine is obsolete when quantitative monitoring and appropriate dosing are used carefully. Cost, availability, and patient-specific factors still matter.
The atelectasis finding is statistically real and clinically soft at the same time. Imaging-defined atelectasis is common after major surgery; whether that slice of the composite translates into fewer long-term harms is still uncertain. I care more about the process measures that sit underneath the headline: complete reversal, timely return of airway reflexes, and avoiding residual paralysis in patients who already carry pulmonary risk.
Clinical takeaways
- SNaPP showed a small but statistically significant reduction in a composite of postoperative pulmonary complications or death with sugammadex versus neostigmine after major abdominal or thoracic surgery.
- Most of the difference came from less atelectasis; pneumonia, aspiration, and death rates were similar.
- Quantitative neuromuscular monitoring remains essential regardless of which reversal agent you choose.
- Consider sugammadex preferentially when residual weakness would be especially hazardous (thoracic/abdominal cases, older patients, limited reserve)—while still individualizing for cost, indication, and monitoring data.
- Do not over-interpret the trial as proof that sugammadex prevents all serious pulmonary morbidity; the absolute benefit was modest.
Source
- Leslie K, et al. Sugammadex versus neostigmine for reversal of neuromuscular blockade and postoperative pulmonary complications (SNaPP). The Lancet Respiratory Medicine. Full text
- Pulmonology Advisor coverage: Postoperative Pulmonary Complications: Sugammadex Outperforms Neostigmine
This post is clinician commentary for educational discussion. It is not medical advice for any reader’s personal care. Anesthesia and perioperative decisions should be made with the treating clinician based on the individual patient’s circumstances.